DK1399744T3 - EPF-receptorassays, forbindelser og terapeutiske præparater - Google Patents

EPF-receptorassays, forbindelser og terapeutiske præparater

Info

Publication number
DK1399744T3
DK1399744T3 DK02745422T DK02745422T DK1399744T3 DK 1399744 T3 DK1399744 T3 DK 1399744T3 DK 02745422 T DK02745422 T DK 02745422T DK 02745422 T DK02745422 T DK 02745422T DK 1399744 T3 DK1399744 T3 DK 1399744T3
Authority
DK
Denmark
Prior art keywords
epf
assays
compounds
test compound
receptor assays
Prior art date
Application number
DK02745422T
Other languages
English (en)
Inventor
Arjan Buist
Eckhard Bender
Tom Julia Leon Meeusen
Elke Jenny Henriette Clynen
Liliane Amelie Henrica Schoofs
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK1399744T3 publication Critical patent/DK1399744T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
DK02745422T 2001-06-27 2002-06-26 EPF-receptorassays, forbindelser og terapeutiske præparater DK1399744T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01202474 2001-06-27
PCT/EP2002/007263 WO2003005036A2 (en) 2001-06-27 2002-06-26 Epf receptor assays, compounds and therapeutic compositions

Publications (1)

Publication Number Publication Date
DK1399744T3 true DK1399744T3 (da) 2008-09-22

Family

ID=8180549

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02745422T DK1399744T3 (da) 2001-06-27 2002-06-26 EPF-receptorassays, forbindelser og terapeutiske præparater

Country Status (16)

Country Link
US (2) US20040235722A1 (da)
EP (1) EP1399744B1 (da)
JP (1) JP4326326B2 (da)
KR (2) KR100977824B1 (da)
CN (1) CN100406891C (da)
AT (1) ATE397218T1 (da)
AU (1) AU2002317013B2 (da)
CA (1) CA2450502C (da)
DE (1) DE60226867D1 (da)
DK (1) DK1399744T3 (da)
ES (1) ES2307767T3 (da)
IL (2) IL158817A0 (da)
NO (1) NO341778B1 (da)
NZ (1) NZ529714A (da)
WO (1) WO2003005036A2 (da)
ZA (1) ZA200309823B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1340979A3 (en) * 2002-02-27 2004-02-04 Pfizer Limited Neuropeptide receptor and uses thereof
AU2004250256B8 (en) * 2003-06-20 2010-04-08 Ambit Biosciences Corporation Assay and kits for detecting protein binding
KR20080098579A (ko) * 2005-08-31 2008-11-11 씨바이오 리미티드 변형된 샤페로닌 10
CN101514335B (zh) * 2008-02-22 2013-04-17 中国科学院生物物理研究所 流感病毒聚合酶亚基pa的表达纯化及pa氨基端及pa羧基端与pb1氨基端多肽复合体的晶体结构
BRPI0911676A2 (pt) * 2008-04-11 2016-11-29 Cbio Ltd polipeptídeo cpn10 isolado, ácido nucléico isolado, construção de expressão, célula hospedeira, anticorpo, composição farmacêutica, método para tratar ou prevenir uma doença, método para modular a sinalização do prr, método para modular a produção e/ou a secreção de um ou mais imunomoduladores, método para inibir a produção e/ou a secreção de um ou mais imunomoduladores, método de identificação de um composto que se liga a um polipeptídeo, método para rastrear um coposto e um ligante de prr e variante funcional, derivado, homólogo, análogo ou fragmento do polipeptídeo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233938T3 (es) * 1993-11-30 2005-06-16 The University Of Queensland Chaperonina 10.
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
SE9704836D0 (sv) * 1997-12-22 1997-12-22 Astra Pharma Inc Novel receptor
CN1296567A (zh) * 1998-02-02 2001-05-23 康瑟普托诊断公司 用于检测动物怀孕的方法和装置
EP1220914A1 (en) * 1999-09-16 2002-07-10 Solvay Pharmaceuticals B.V. Human g-protein coupled receptor
IL149569A0 (en) * 1999-11-17 2002-11-10 Arena Pharm Inc Endogenous and non-endogenous versions of human g protein-coupled receptors

Also Published As

Publication number Publication date
CN100406891C (zh) 2008-07-30
KR100977824B1 (ko) 2010-08-25
IL158817A0 (en) 2004-05-12
EP1399744A2 (en) 2004-03-24
CA2450502C (en) 2017-10-31
JP4326326B2 (ja) 2009-09-02
CN1541335A (zh) 2004-10-27
IL158817A (en) 2012-01-31
KR20090111346A (ko) 2009-10-26
EP1399744B1 (en) 2008-05-28
WO2003005036A2 (en) 2003-01-16
ES2307767T3 (es) 2008-12-01
NO20035771L (no) 2004-02-26
NO341778B1 (no) 2018-01-15
WO2003005036A3 (en) 2003-10-16
ATE397218T1 (de) 2008-06-15
KR20040010644A (ko) 2004-01-31
US20060160145A1 (en) 2006-07-20
CA2450502A1 (en) 2003-01-16
JP2005503543A (ja) 2005-02-03
DE60226867D1 (de) 2008-07-10
NZ529714A (en) 2008-04-30
ZA200309823B (en) 2005-05-25
HK1070694A1 (zh) 2005-06-24
US7402563B2 (en) 2008-07-22
US20040235722A1 (en) 2004-11-25
KR100971270B1 (ko) 2010-07-20
AU2002317013B2 (en) 2007-11-01

Similar Documents

Publication Publication Date Title
EP1708745A4 (en) ANTIBODIES FOR ONCOGENIC STRAINS OF HPV AND METHOD FOR THEIR USE
Andersen et al. Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules
DK1421389T3 (da) Neurofibrilmarkører
ATE343591T1 (de) Antagonist für die multimerisierung von hiv-1 vif-protein
NO20072721L (no) Polypeptides that bind BR3 and uses thereof
Wu et al. Functional proteomics approaches for the identification of transnitrosylase and denitrosylase targets
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
NO941485L (no) Fremgangsmåte for in vivo måling av konsentrasjonen av NMR-påviselig xenobiotisk forbindelse
DK0717850T3 (da) Assaykit
EA200200949A1 (ru) Метаболиты агониста/антагониста эстрогена
DE602007010266D1 (de) Hemmung von gasc1
Amin et al. Correlation between tissue transglutaminase antibodies and endomysium antibodies as diagnostic markers of coeliac disease
CA2524002A1 (en) Sars-related proteins
SE0000675D0 (sv) Monoclonal antibodies
NO20035771L (no) Assays for EPF-reseptorforbindelser samt terapeutiske sammensetninger
ATE304607T1 (de) Nachweis des pyruvatkinase-isoenzyms im stuhl
DE60235011D1 (de) Assays für den präimplantationsfaktor und präimplantationsfaktorpeptide
ATE378411T1 (de) Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen
WO2005103713A3 (en) Methods, compositions and compound assays for inhibiting amyloid-beta protein production
DE60336427D1 (de) Immunoassay-verfahren
DK0811165T3 (da) Detektion af antistofproduktion
DK1095275T3 (da) Endogen, konstitutivt aktiverede G-protein-koblede orphan-receptorer
Lee et al. Development of ELISA system for screening of specific binding inhibitors for Src homology (SH) 2 domain and phosphotyrosine interactions
SE0303581D0 (sv) Novel use of positively charged support
WO2006023211A3 (en) Antigens targeted by pathogenic ai4 t cells in type 1 diabetes and uses thereof